Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Special Report
  • Published:

Targeting leukemia stem cells with HDAC inhibitors and modulators of the DNA damage response

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

    Article  CAS  Google Scholar 

  2. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 2010; 17: 427–442.

    Article  Google Scholar 

  3. Glozak MA, Sengupta N, Zhang X, Seto E . Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15–23.

    Article  CAS  Google Scholar 

  4. Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Mol Cancer Res 2006; 4: 563–573.

    Article  CAS  Google Scholar 

  5. Robert C, Rassool FV . HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res 2012; 116: 87–129.

    Article  CAS  Google Scholar 

  6. Koprinarova M, Botev P, Russev G . Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair (Amst) 2011; 10: 970–977.

    Article  CAS  Google Scholar 

  7. Branzei D, Foiani M . Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008; 9: 297–308.

    Article  CAS  Google Scholar 

  8. Lee JH, Choy ML, Ngo L, Venta-Perez G, Marks PA . Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2011; 108: 19629–19634.

    Article  CAS  Google Scholar 

  9. Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther 2013; 12: 878–889.

    Article  CAS  Google Scholar 

  10. Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD et al. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov 2012; 2: 524–539.

    Article  CAS  Google Scholar 

  11. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796–3800.

    Article  CAS  Google Scholar 

  12. DeAngelo DJ, Erba HP, Maris MB, Swords RT, Anwer F, Altman JK et al. The novel, investigational NEDD8-activating enzyme inhibitor MLN4924 in adult patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndromes (MDS): a phase 1 study. Blood 116: 658.

  13. Blank J, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H et al. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 2012; 73: 225–234.

    Article  Google Scholar 

Download references


The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital.

Author information

Authors and Affiliations


Corresponding author

Correspondence to S Grant.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grant, S. Targeting leukemia stem cells with HDAC inhibitors and modulators of the DNA damage response. Leukemia Suppl 3 (Suppl 1), S14–S15 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:



Quick links